Aspirin cardio tab. p / o ksh / sol. 100mg No. 28
Package quantity, pcs:
28
56
Category
Anticoagulants
Scope of the drug
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Germany
Package quantity, pcs
28
Release form, composition and packaging
?
Enteric-coated tablets, white, round, biconvex
cross-section - a homogeneous mass of white, surrounded by a white shell.
1 tab.
acetylsalicylic acid 100 mg
cellulose, powder - 10 mg, corn starch - 10 mg.
The composition of the enteric shell: copolymer of methacrylic acid and ethyl acrylate (1: 1) - 7.857 mg, polysorbate 80 - 0.186 mg, sodium lauryl sulfate - 0.057 mg, talc - 8.1 mg, triethyl citrate - 0.8 mg.
10 pieces.
- blisters (2) - cardboard packs.
14 pcs.
- blisters (2) - cardboard packs.
14 pcs.
- blisters (4) - cardboard packs.
14 pcs.
- blisters (7) - cardboard packs.
pharmachologic effect
The mechanism of the antiplatelet action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase (COX-1), as a result of which the synthesis of thromboxane A2 is blocked and platelet aggregation is suppressed.
The antiplatelet effect is most pronounced in platelets, because
they are unable to re-synthesize COX.
It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands the scope of its application in various vascular diseases.
ASA also has anti-inflammatory, analgesic and antipyretic effects.
Pharmacokinetics
Absorption After oral administration, ASA is rapidly and completely absorbed from the gastrointestinal tract. ASA is partially metabolized during absorption. During and after absorption, ASA is converted into the main metabolite - salicylic acid. Due to the fact that the tablets are coated with an acid-resistant coating, ASA is released not in the stomach, but in the alkaline environment of the duodenum. Cmax of ASA in blood plasma is achieved approximately 2-7 hours after taking the tablets, thus, the absorption of ASA in the form of enteric-coated tablets is slowed down compared to the usual (without an enteric coating). When taken simultaneously with food, a slowdown in the absorption of ASA is noted without affecting the degree of absorption. Lower absorption rate of enteric-coated ASA tablets,does not affect the exposure of ASA in blood plasma and its ability to inhibit platelet aggregation during long-term therapy with low doses of the drug. Nevertheless, in order to ensure maximum stability of Aspirin® Cardio tablets in the stomach, it is recommended to take the drug 30 minutes before a meal with plenty of liquid (see section Dosage regimen"). According to pharmacokinetic data, there are no clinically significant deviations in the concentration-dose curve when taking ASA at a dose of 100 mg to 500 mg. Distribution ASA and salicylic acid bind to a large extent with blood plasma proteins and are rapidly distributed in the body. Salicylic acid crosses the placental barrier, excreted in breast milk. Metabolism The main metabolite of ASA is salicylic acid.The metabolism of salicylic acid is carried out in the liver with the formation of salicyrulic acid, phenolic glucuronide of salicylic acid, salicylglucuronide and gentisuric acid. Elimination The elimination of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. T1 / 2 ranges from 2-3 hours when using ASA in low doses and up to 15 hours when using the drug in high doses (usual doses of acetylsalicylic acid as an analgesic). Salicylic acid and its metabolites are excreted by the kidneys.T1 / 2 ranges from 2-3 hours when using ASA in low doses and up to 15 hours when using the drug in high doses (usual doses of acetylsalicylic acid as an analgesic). Salicylic acid and its metabolites are excreted by the kidneys.T1 / 2 ranges from 2-3 hours when using ASA in low doses and up to 15 hours when using the drug in high doses (usual doses of acetylsalicylic acid as an analgesic). Salicylic acid and its metabolites are excreted by the kidneys.
Indications for use
- primary prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction
- unstable angina pectoris (including suspected development of acute myocardial infarction) and stable angina pectoris
- stroke prevention (including in patients with transient cerebrovascular accident)
- prevention
Name ENG
ASPIRIN CARDIO
Clinical and pharmacological group
Antiplatelet agent
ATX code
Acetylsalicylic acid
Dosage
100mg
Structure
1 tablet contains acetylsalicylic acid 100 mg
Indications
primary prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction
unstable angina (including suspected development of acute myocardial infarction) and stable angina
stroke prevention (including in patients with transient cerebrovascular accident)
prevention of transient disorders of cerebral circulation
prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, endarterectomy of the carotid arteries, arteriovenous bypass grafting, angioplasty and stenting of the coronary arteries, angioplasty of the carotid arteries)
prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including with prolonged immobilization as a result of extensive surgical intervention).
Contraindications
hypersensitivity to acetylsalicylic acid, excipients in the drug and other NSAIDs
bronchial asthma induced by the intake of salicylates and other NSAIDs
a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and ASA intolerance
erosive and ulcerative lesions of the gastrointestinal tract in the acute phase
gastrointestinal bleeding
hemorrhagic diathesis
severe renal impairment
severe liver dysfunction
chronic heart failure III-IV FC according to NYHA classification
combined use with methotrexate at a dose of 15 mg per week or more
I and III trimesters of pregnancy
lactation period (breastfeeding)
children and adolescents up to 18 years of age (due to the lack of data on efficacy and safety).,
Carefully:
hypersensitivity to analgesics, anti-inflammatory drugs, antirheumatic drugs, as well as allergic reactions to other substances
a history of ulcerative lesions of the gastrointestinal tract, incl.
a history of chronic and recurrent gastrointestinal lesions or gastrointestinal bleeding
with gout, hyperuricemia
with impaired liver function
with impaired renal function
with circulatory disorders resulting from atherosclerosis of the renal arteries, congestive heart failure, hypovolemia, extensive surgery, sepsis, cases of massive bleeding
with bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, chronic diseases of the respiratory system, as well as allergic reactions to other drugs (for example, skin reactions, itching, urticaria)
with severe forms of glucose-6-phosphate dehydrogenase deficiency
in the II trimester of pregnancy
with the proposed surgical intervention (including minor, for example, tooth extraction)
when used in combination with the following drugs:
- with methotrexate at a dose of less than 15 mg per week
- with anticoagulant, thrombolytic or other antiplatelet agents
- with NSAIDs (including ibuprofen, naproxen)
- with digoxin
- with hypoglycemic agents for oral administration (sulfonylurea derivatives) and insulin
- with valproic acid
- with alcohol (alcoholic beverages in particular)
- with selective serotonin reuptake inhibitors.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 5 years
INN / Active ingredient
acetylsalicylic acid
Specifications
Category
Anticoagulants
Scope of the drug
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Germany
Package quantity, pcs
28
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Bayer
The amount of the dosage form in the primary package
14 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antiplatelet agent
Anatomical and therapeutic characteristics
B01AC06 Acetylsalicylic acid
Dosage form
Enteric-coated tablets
Dosage (volume) of the substance in the preparation
acetylsalicylic acid 100 mg
Expiration date in days
1825
Package weight, g
twenty
Mode of application
:
Aspirin cardio is prescribed by mouth. For prophylaxis with suspected acute myocardial infarction, the recommended dose is 100-200 mg / day or 300 mg every other day. The first tablet is recommended to be chewed for faster absorption. For the prevention of new-onset acute myocardial infarction in the presence of risk factors, the recommended dose is 100 mg / day or 300 mg every other day. For the prevention of recurrent myocardial infarction, with unstable angina pectoris, for the prevention of stroke, transient cerebrovascular accident and thromboembolic complications after surgical interventions on the vessels, the drug is prescribed at a dose of 100-300 mg / day. For the prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches, the recommended dose of the drug is 100-200 mg / day or 300 mg every other day.Aspirin Cardio is intended for long-term use, the duration of therapy is set individually. Aspirin Cardio tablets are taken before meals with plenty of liquid.
Information on technical characteristics, delivery set, country of manufacture "